Stem Cell Trials – Should They Go Ahead? Why Harm to Patients Is Not a Reason to Stop Them
Professor Savulescu comments:
Professor Julian Savulescu is Uehiro Chair in Practical Ethics and Director of the Uehiro Centre for Practical Ethics at Oxford, Director of the Oxford Centre for Neuroethics, and Director of the Program on the Ethics of the New Biosciences. He was also recently awarded a major Arts and Humanities Research Council grant on Cognitive Science and Religious Conflict.
THE FDA has approved for the first time a clinical trial of embryonic stem cells to treat spinal injury patients. The trial will be conducted by Geron. A similar trial by Reneuron has been approved recently in the UK (The Scotsman, and the BBC). The research in the UK to treat stroke patients has already attracted stern criticism from “ethical campaigners.” The first wave predictably objected on the ground that it involved abortion "It involves cannibalising an unborn child.” But no child was aborted for the purposes of providing stem cells. These would have involved abortions that would anyway have occurred for a variety of reasons. Such opponents predictably object to anything involving destruction of embryos and fetuses – abortion, IVF, prenatal testing, contraception – so it is hardly surprising that they would object to this form of medical treatment.
The second wave of ethical campaigners, not clearly distinct from the first, claim now that the treatment is too risky. But is it too risky?